# A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

> **NCT04320615** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 452 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Tocilizumab (TCZ)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04320615
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-03
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-07-28
- **Target enrollment:** 452 (ACTUAL)
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320615, "A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04320615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*